GlycoMimetics Ownership
| GLYC Stock | USD 0.24 0.01 4.00% |
Shares in Circulation | First Issued 2012-09-30 | Previous Quarter 64.5 M | Current Value 64.5 M | Avarage Shares Outstanding 35.6 M | Quarterly Volatility 19.8 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
GlycoMimetics |
GlycoMimetics Stock Ownership Analysis
About 48.0% of the company shares are owned by institutional investors. The company has price-to-book (P/B) ratio of 1.35. Some equities with similar Price to Book (P/B) outperform the market in the long run. GlycoMimetics recorded a loss per share of 0.62. The entity had not issued any dividends in recent years. GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland. Glycomimetics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 52 people. To learn more about GlycoMimetics call Rachel King at 240 243 1201 or check out https://www.glycomimetics.com.Besides selling stocks to institutional investors, GlycoMimetics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different GlycoMimetics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align GlycoMimetics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
GlycoMimetics Quarterly Liabilities And Stockholders Equity |
|
Roughly 3.0% of GlycoMimetics are currently held by insiders. Unlike GlycoMimetics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against GlycoMimetics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of GlycoMimetics' insider trades
GlycoMimetics Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as GlycoMimetics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading GlycoMimetics backward and forwards among themselves. GlycoMimetics' institutional investor refers to the entity that pools money to purchase GlycoMimetics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Intellectus Partners, Llc | 2024-09-30 | 46 K | Adar1 Capital Management Llc | 2024-09-30 | 45.7 K | Two Sigma Investments Llc | 2024-09-30 | 44.6 K | Ieq Capital, Llc | 2024-09-30 | 38.4 K | Group One Trading, Lp | 2024-09-30 | 38 K | Hrt Financial Llc | 2024-09-30 | 32.3 K | Lpl Financial Corp | 2024-09-30 | 30.7 K | Jane Street Group Llc | 2024-06-30 | 29.7 K | Xtx Topco Ltd | 2024-09-30 | 24.9 K | Bvf Inc | 2024-09-30 | 9.5 M | Vanguard Group Inc | 2024-09-30 | 2.7 M |
GlycoMimetics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific GlycoMimetics insiders, such as employees or executives, is commonly permitted as long as it does not rely on GlycoMimetics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases GlycoMimetics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
GlycoMimetics Outstanding Bonds
GlycoMimetics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. GlycoMimetics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most GlycoMimetics bonds can be classified according to their maturity, which is the date when GlycoMimetics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether GlycoMimetics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of GlycoMimetics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Glycomimetics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Glycomimetics Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlycoMimetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. For information on how to trade GlycoMimetics Stock refer to our How to Trade GlycoMimetics Stock guide.You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlycoMimetics. If investors know GlycoMimetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlycoMimetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.62) | Quarterly Revenue Growth (1.00) | Return On Assets (0.59) | Return On Equity (1.04) |
The market value of GlycoMimetics is measured differently than its book value, which is the value of GlycoMimetics that is recorded on the company's balance sheet. Investors also form their own opinion of GlycoMimetics' value that differs from its market value or its book value, called intrinsic value, which is GlycoMimetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlycoMimetics' market value can be influenced by many factors that don't directly affect GlycoMimetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GlycoMimetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if GlycoMimetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlycoMimetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.